Yao Yihong 4
4 · Cellular Biomedicine Group, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
Yao Yihong
Chief Scientific Officer
Transactions
- Disposition to Issuer
Common Stock
2021-02-19−18,900→ 0 total - Other
Employee Stock Option (Right to Buy)
2021-02-19−25,000→ 0 totalExercise: $26.53From: 2016-08-04Exp: 2025-08-04→ Common Stock (25,000 underlying) - Other
Employee Stock Option (Right to Buy)
2021-02-19−10,000→ 0 totalExercise: $18.61Exp: 2026-04-08→ Common Stock (10,000 underlying) - Other
Employee Stock Option (Right to Buy)
2021-02-19−26,500→ 0 totalExercise: $12.40Exp: 2027-03-03→ Common Stock (26,500 underlying) - Award
Common Stock
2021-02-19+54,000→ 107,449 total - Other
Common Stock
2021-02-19−88,549→ 18,900 total
Footnotes (7)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among Cellular Biomedicine Group, Inc. (the "Company"), CBMG Holdings ("Parent") and CBMG Merger Sub Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the "Merger"). The Merger became effective on February 19, 2021 (the "Closing Date").
- [F2]Effective March 3, 2017, the Reporting Person was granted performance-based restricted stock units, which, as a result of the Merger, were accelerated and vested in full at the maximum level of performance on the Closing Date.
- [F3]Pursuant to an agreement between the Reporting Person and Parent, 88,549 shares of common stock held by the Reporting Person were converted into shares of common stock of Parent.
- [F4]Pursuant to terms of the Merger Agreement, at the effective time of the Merger, 18,900 shares of common stock of held by the Reporting Person were cancelled and exchanged for the right to receive merger consideration of $19.75 in cash per share.
- [F5]Pursuant to an agreement between the Reporting Person and Parent, the 61,500 stock options held by the Reporting Person were converted into an option to acquire ordinary shares of Parent.
- [F6]This option vested according to the following schedule: 3,000 shares vested and became fully exercisable on April 8, 2017, 3,000 shares vested and became fully exercisable on April 8, 2018, and 4,000 shares vested and became fully exercisable on April 8, 2019.
- [F7]This option vests over a period of four years according to the following schedule: 1/48th per month following the vesting commencement date of March 27, 2017. In connection with the Merger, unvested options were accelerated and vested in full at the effective time of the Merger.